KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash & Equivalents (2016 - 2025)

Moderna (MRNA) has disclosed Cash & Equivalents for 10 consecutive years, with $2.6 billion as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 34.67% to $2.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 billion through Dec 2025, up 34.67% year-over-year, with the annual reading at $2.6 billion for FY2025, 34.67% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $2.6 billion at Moderna, up from $1.1 billion in the prior quarter.
  • The five-year high for Cash & Equivalents was $6.8 billion in Q4 2021, with the low at $1.1 billion in Q3 2025.
  • Average Cash & Equivalents over 5 years is $3.3 billion, with a median of $2.9 billion recorded in 2023.
  • The sharpest move saw Cash & Equivalents skyrocketed 1288.27% in 2021, then plummeted 53.2% in 2022.
  • Over 5 years, Cash & Equivalents stood at $6.8 billion in 2021, then tumbled by 53.2% to $3.2 billion in 2022, then decreased by 9.3% to $2.9 billion in 2023, then plummeted by 33.71% to $1.9 billion in 2024, then surged by 34.67% to $2.6 billion in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $2.6 billion, $1.1 billion, and $1.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.